Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

National Glaucoma Research - Current Award

Dr. Ron Ofri

Ron Ofri, Ph.D.

Hebrew University of Jerusalem
Jerusalem, Israel

Title: Expression of ion channels during ganglion cell apoptosis. Implications for the pathogenesis of glaucomatous optic neuropathy and relevance for neuroprotective treatment
Non-Technical Title: The role of electric current changes in loss of vision in glaucoma patients, and their implication for treatment

Duration: April 1, 2008 - March 31, 2010
Award Type: Standard
Award Amount: $100,000


Summary:

This study investigates the ability of an epilepsy drug to reduce cell death related to glaucoma.

Details:

Loss of vision in glaucoma patients is caused by death of ganglion cells in the retina. Therefore, preventing the death of these cells may preserve vision. To develop a drug to prevent cell death there must be an understanding of this process. The researchers believe that changes in electrical currents may be the 'trigger' that leads to cell death in glaucoma. Preventing these changes may halt cell death and loss of vision. Lamotrigine (used to treat epilepsy) is such an inhibitor. It will be tested in a rat glaucoma model to investigate its effect on the function and structure of the retina, and on molecular and genetic events in the ganglion cells. Positive results may lead to human testing.